Skip to main content

Annual Drug Utilization Reports

Drug Utilization Reports offer data regarding dispensed controlled substance prescriptions reported to MAPS. In 2020, the number of opioid prescriptions dispensed decreased by 38.5 percent since 2015. Effective January 4, 2019, gabapentin was classified as a Schedule 5 controlled substance and accounts for 2,271,317 (12.3%) of all 2019 controlled substance prescriptions reported to MAPS, and 2,297,670 (12.9%) of all 2020 controlled substance prescriptions reported to MAPS.

 

Total CS prescriptions dispensed

% change from previous year

2007

17,007,858

 

2008

17,400,640

2.31%

2009

17,876,684

2.74%

2010

18,954,172

6.03%

2011

19,763,680

4.27%

2012

20,991,020

6.21%

2013

20,728,216

-1.25%

2014

20,904,764

0.85%

2015

21,472,326

2.71%

2016

21,092,674

-1.77%

2017 19,943,203 -5.45%

2018 (updated Nov 5, 2019)

17,623,754

-11.63%

2019 18,472,677 4.82%
2020 17,785,603 -3.72%

Select the years below to access individual drug utilization reports.

Statewide Opioid Assessment

A new statewide assessment has identified trends that will assist government agencies, lawmakers and local community leaders tailor laws, target resources, and design innovative programs to best address the opioid epidemic in Michigan.

The assessment overlays three years (2013-2015) of well-documented cases of unintentional overdose death with five years (2012-2017) of prescription records in the Michigan Automated Prescription System (MAPS). In total, more than 7.5 million patients receiving 103.2 million prescriptions over the last five years were linked to 5,261 overdose deaths.

The assessment provides valuable information about patterns of opioid usage in Michigan by detailing patient-level and aggregate trends of controlled-substance prescriptions and overdose deaths within the state.

READ THE FULL ASSESSMENT

NarxCare Effectiveness Study

A new study, the Michigan AWARxE/NarxCare Implementation Evaluation, is the nation’s first study evaluating the effectiveness of NarxCare. Appriss’s Michigan Implementation and Evaluation analyzes NarxCare risk scores and shows a decline in patients with a high potential to abuse prescription drugs.

READ THE FULL ASSESSMENT

CONTACT MAPS

Telephone: 517-241-0166

Fax: 517-241-5072

Email: BPL-MAPS@michigan.gov

MAPS INTEGRATION

The State of Michigan is covering the full cost of integration of MAPS into the clinical workflow of health systems, physician groups and pharmacies until August 31, 2023. Learn how to start the integration process.

MAPS LEGISLATION

If your question(s) pertain to the new opioid legislation, we encourage you to review the recently-released FAQs. Additional questions or concerns can be addressed by contacting MAPS.